Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Timing of quality of life (QoL) assessments as a source of error in oncological trials.
Hakamies-Blomqvist L, Luoma ML, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Østenstad B, Mjaaland I, Ottosson S, Bergh J, Malmström PO, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: mjaaland i. J Adv Nurs. 2001 Sep;35(5):709-16. doi: 10.1046/j.1365-2648.2001.01903.x. J Adv Nurs. 2001. PMID: 11529973
Quality of life in patients with metastatic breast cancer receiving either docetaxel or sequential methotrexate and 5-fluorouracil. A multicentre randomised phase III trial by the Scandinavian breast group.
Hakamies-Blomqvist L, Luoma M, Sjöström J, Pluzanska A, Sjödin M, Mouridsen H, Ostenstad B, Mjaaland I, Ottosson-Lönn S, Bergh J, Malmström P, Blomqvist C. Hakamies-Blomqvist L, et al. Among authors: mjaaland i. Eur J Cancer. 2000 Jul;36(11):1411-7. doi: 10.1016/s0959-8049(00)00126-x. Eur J Cancer. 2000. PMID: 10899655 Clinical Trial.
Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.
Sjöström J, Blomqvist C, Mouridsen H, Pluzanska A, Ottosson-Lönn S, Bengtsson NO, Ostenstad B, Mjaaland I, Palm-Sjövall M, Wist E, Valvere V, Anderson H, Bergh J. Sjöström J, et al. Among authors: mjaaland i. Eur J Cancer. 1999 Aug;35(8):1194-201. doi: 10.1016/s0959-8049(99)00122-7. Eur J Cancer. 1999. PMID: 10615229 Clinical Trial.
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer.
Sjöström J, Collan J, von Boguslawski K, Franssila K, Bengtsson NO, Mjaaland I, Malmström P, Østenstad B, Wist E, Valvere V, Bergh J, Skiöld-Petterson D, Saksela E, Blomqvist C. Sjöström J, et al. Among authors: mjaaland i. Eur J Cancer. 2002 Mar;38(4):535-42. doi: 10.1016/s0959-8049(01)00403-8. Eur J Cancer. 2002. PMID: 11872346 Clinical Trial.
Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.
Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE. Chrisanthar R, et al. Among authors: mjaaland i. PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249. PLoS One. 2011. PMID: 21556366 Free PMC article. Clinical Trial.
Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.
Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE. Knappskog S, et al. Among authors: mjaaland i. Breast Cancer Res. 2012 Mar 15;14(2):R47. doi: 10.1186/bcr3147. Breast Cancer Res. 2012. PMID: 22420423 Free PMC article. Clinical Trial.
50 results